| Literature DB >> 24678809 |
Sebastian Spethmann1, Karl Rieper, Gabriela Riemekasten, Adrian C Borges, Sebastian Schattke, Gerd-Ruediger Burmester, Bernd Hewing, Gert Baumann, Henryk Dreger, Fabian Knebel.
Abstract
BACKGROUND: Subclinical myocardial involvement is common in systemic sclerosis (SSc) and associated with poor prognosis. Early detection, particularly during follow-up, is important. Two-dimensional speckle tracking echocardiography (STE) has already been shown to detect early left ventricular systolic impairment in SSc patients with advanced disease. The aim of this study was to assess the ability of STE to diagnose changes in left ventricular function in patients with SSc with preserved LV ejection fraction (LVEF) and normal pulmonary pressure over time.Entities:
Mesh:
Year: 2014 PMID: 24678809 PMCID: PMC3986623 DOI: 10.1186/1476-7120-12-13
Source DB: PubMed Journal: Cardiovasc Ultrasound ISSN: 1476-7120 Impact factor: 2.062
Clinical and biological characteristics of SSc patients
| Age, (years) | 55.2 ± 10.8 |
| Sex (female), [n (%)] | 13 (68.4%) |
| Disease duration, (years) | 60 ± 4.5 |
| Time of follow-up examination after baseline examination, (days) | 756.6 ± 8.8 |
| Time of baseline echocardiography between right heart catheter, (days) | 6.0 ± 10.4 |
| Body mass index (kg/m2) | 24.0 ± 2.7 |
| Arterial hypertension, [n (%)] | 4 (21.1) |
| Smoker, [n (%)] | 2 (10.5) |
| Raynaud’s syndrom, [n (%)] | 8 (42.1) |
| Modified Rodnan Skin Score | 8.2 ± 6.5 |
| Anti-centromere antibodies, [n (%)] | 4 (21.1) |
| Anti-Scl-70 antibodies, [n (%)] | 7 (36.8) |
| Pulmonary fibrosis, [n (%)] | 8 (42.1) |
| Impaired renal function, [n (%)] | 2 (10.5) |
| | |
| Cardiac output, (l/min) | 5.4 ± 0.7 |
| Cardiac index, (l/min/m2) | 3.0 ± 0.4 |
| PAP systolic, (mmHg) | 27.3 ± 4.9 |
| PAP diastolic, (mmHg) | 11.2 ± 3.1 |
| PAP mean, (mmHg) | 17.7 ± 3.5 |
| PCWP mean, (mmHg) | 10.1 ± 3.6 |
| SVR, (dyn × sec × cm-5) | 2203.3 ± 787.7 |
| PVR, (dyn × sec × cm-5) | 188.3 ± 98.6 |
Data are expressed as mean ± SD, except gender, hypertension, and except disease duration and time of follow-up examination, which are expressed as median ± SD. SSc, systemic sclerosis; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance.
Conventional echocardiographic data
| Heart rate, (bmp) | 71.2 ± 11.5 | 69.7 ± 8.8 | ns |
| LVEDV, (ml) | 62.9 ± 21.4 | 71.8 ± 28.5 | ns |
| LVESV, (ml) | 23.5 ± 9.3 | 27.0 ± 13.7 | ns |
| LV mass index, (g/m2) | 89.2 ± 14.3 | 93.8 ± 19.5 | ns |
| Aortic valve peak instantaneous velocity, (m/s) | 1.3 ± 0.2 | 1.4 ± 0.3 | ns |
| E, (m/s) | 0.70 ± 0.16 | 0.70 ± 0.15 | ns |
| A, (m/s) | 0.69 ± 0.14 | 0.74 ± 0.14 | ns |
| E/A | 1.0 ± 0.3 | 1.0 ± 0.2 | ns |
| E’, (cm/s) | 8.5 ± 2.1 | 8.4 ± 2.3 | ns |
| A’, (cm/s) | 9.3 ± 1.9 | 9.4 ± 2.1 | ns |
| E/E’ | 8.4 ± 2.0 | 8.8 ± 2.8 | ns |
| DT, (ms) | 183.1 ± 50.8 | 176.9 ± 37.6 | ns |
Data are expressed as mean ± SD. LVEDV, left ventricular enddiastolic volume; LVESV, left ventricular endsystolic volume; LV left ventricular; DT, deceleration time.
Left ventricular ejection fraction, pw DTI and speckle tracking strain data
| LVEF, (%) | 63.3 ± 4.2 | 63.2 ± 5.0 | ns |
| Peak systolic velocity (cm/s) | 7.7 ± 1.5 | 7.8 ± 1.7 | ns |
| Global longitudinal PSS, (%) | -22.0 ± 2.3 | -20.8 ± 2.1 | 0.04 |
| APLAX, (%) | -21.5 ± 3.5 | -20.3 ± 2.7 | ns |
| 4CH, (%) | -22.1 ± 2.5 | -19.8 ± 3.5 | 0.006 |
| 2CH, (%) | -22.2 ± 2.7 | -21.7 ± 2.6 | ns |
Data are expressed as mean ± SD. Pw DTI, pulsed wave doppler tissue imaging; PSS, peak systolic strain; APLAX, apical long axis view; 4CH, apical four chamber view; 2CH, apical two-chamber view; LVEF, left ventricular ejection fraction.
Figure 1Global longitudinal peak systolic strain (PSS) (A) and left ventricular ejection fraction (B) in systemic sclerosis (SSc) patients at baseline and at follow up.
Figure 2Intraindividual course of the global longitudinal peak systolic strain at baseline (Left Panel) and at follow-up (Right Panel).
Regional longitudinal strain data
| Basal segments, (%) | -20.3 ± 3.0 | -18.8 ± 2.8 | 0.053 |
| APLAX, (%) | -19.7 ± 4.0 | -18.4 ± 3.9 | 0.286 |
| 4CH, (%) | -19.7 ± 3.7 | 18.2 ± 3.3 | 0.076 |
| 2CH, (%) | -22.4 ± 3.6 | -20.2 ± 3.5 | 0.053 |
| Medial segments, (%) | -21.7 ± 2.3 | -21.1 ± 2.6 | 0.243 |
| APLAX, (%) | -21.4 ± 3.1 | -20.9 ± 3.0 | 0.687 |
| 4CH, (%) | -21.9 ± 2.9 | -20.6 ± 3.1 | 0.011 |
| 2CH, (%) | -21.4 ± 2.8 | -21.8 ± 3.5 | 0.687 |
| Apical segments, (%) | -23.8 ± 2.9 | -22.2 ± 2.6 | 0.053 |
| APLAX, (%) | -22.6 ± 5.0 | -21.6 ± 5.1 | 0.717 |
| 4CH, (%) | -24.5 ± 4.0 | -22.4 ± 4.4 | 0.113 |
| 2CH, (%) | -23.7 ± 3.6 | -22.9 ± 3.1 | 0.807 |
Data are expressed as mean ± SD. PSS, Peak systolic strain; APLAX, apical long axis view; 4CH, apical four-chamber view; 2CH, apical two-chamber view.
Figure 3Colour-coding of the average regional longitudinal peak systolic strain in patients with SSC at baseline (Left Panel) and at follow-up (Right Panel). A: The apical long axis view. B: The four chamber view. C: The two chamber view.
Figure 4Bull’s-eye diagram of a patient with SSc at baseline and at follow-up. Left Panel (A): a global longitudinal peak systolic strain of -21.6% at baseline. Right Panel (B): a global longitudinal peak systolic strain of -16.1% at follow-up (Right Panel, B).